NCT05184842 · OUTCOME

Percentage of Participants With Complete Remission (CR) and Complete Remission With Incomplete Hematologic Recovery (CRi)

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML · Source last updated 2026-01-05

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Up to 3 months

What was measured

Percentage of participants with CR + CRi will be calculated based on current International Working Group (IWG) criteria. CR is defined as absolute neutrophil count (ANC) \> 1000/microliter (mcL), platelets \> 100,000/mcL, red cell transfusion independence, and bone marrow with \< 5% blasts. CRi is defined as bone marrow with less than 5% blasts, and absolute neutrophils of ≤ 1000/mcL or platelets ≤ 100,000/mcL.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: Percentage of participants with CR + CRi will be calculated based on current International Working Group (IWG) criteria. CR is defined as absolute neutrophil count (ANC) \> 1000/microliter (mcL), platelets \> 100,000/mcL, red cell transfusion independence, and bone marrow with \< 5% blasts. CRi is defined as bone marrow with less than 5% blasts, and absolute neutrophils of ≤ 1000/mcL or platelets ≤ 100,000/mcL.
reporting Status: NOT_POSTED
time Frame: Up to 3 months
title: Percentage of Participants With Complete Remission (CR) and Complete Remission With Incomplete Hematologic Recovery (CRi)
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice